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Background: To report outcomes in women with locally recurrent or advanced cervical cancer who received
intraoperative electron beam radiotherapy (IOERT) as a component of therapy.
Methods: From 1983 to 2010, 86 patients with locally recurrent (n = 73, 85%) or primary advanced (n = 13, 15%)
cervical cancer received IOERT following surgery. Common surgeries included pelvic exenteration (n = 26; 30%) or
sidewall resection (n = 22; 26%). The median IOERT dose was 15 Gy (range, 6.25-25 Gy). Sixty-one patients (71%)
received perioperative external beam radiotherapy (EBRT; median dose, 45 Gy). Forty-one patients (48%) received
perioperative chemotherapy.
Results: Median follow-up was 2.7 years (range, 0.1-25.5 years). Resections were classified as R0 (n = 35, 41%), R1
(n = 30, 35%), or R2 (n = 21, 24%). Cumulative incidences of central (within the IOERT field) and locoregional relapse
at 3 years were 23 and 38%, respectively. The 3-year cumulative incidence of distant relapse was 43%. Median
survival was 15 months, and 3-year Kaplan-Meier estimates of cause-specific (CSS) and overall survival (OS) were 31
and 25%, respectively. On multivariate analysis, pelvic exenteration (p = 0.02) and perioperative EBRT (p = 0.009)
were associated with improved central control in patients with recurrent disease. Recurrence within 6 months of
initial therapy was associated with reduced CSS (p = 0.001). Common IOERT-related toxicities included peripheral
neuropathy (n = 16), ureteral stenosis (n = 4), and bowel fistula/perforation (n = 4). Eleven of 16 patients with
neuropathy required long-term pain medication.
Conclusions: Long-term survival is possible with combined modality therapy including IOERT for advanced cervical
cancer. Distant relapse is common, yet a significant number of patients experienced local progression in spite of
aggressive treatment. In addition to consideration of disease- and treatment-related morbidity, other factors to be
considered when selecting patients for this approach include the time interval from initial therapy to recurrence
and whether the patient is able to receive perioperative EBRT and pelvic exenteration in addition to IOERT.
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The incidence of cervical cancer in the United States con-
tinues to decline, with an estimated 12,170 cases of inva-
sive cancer to be diagnosed in 2012 [1]. Unfortunately,
cervical cancer continues to be the leading cause of cancer
mortality in women in developing countries, resulting in
approximately 190,000 deaths per year [2]. While the
prognosis for early-stage disease is excellent, with 5-year
survival rates approaching 90% [3], the prognosis for lo-
cally advanced disease with pelvic sidewall or locoregional
lymph node involvement is poor [4,5]. This is also true for
women with locally recurrent cancer, where poor prognos-
tic factors include pelvic sidewall fixation, early recurrence
after primary therapy, and tumor recurrence >3 cm in
greatest dimension [6-8].
The importance of achieving local control in patients
with cervical cancer cannot be overemphasized, as more
than half of recurrences after primary therapy are limited
to the pelvis [9]. Furthermore, persistent pelvic disease
may result in significant morbidity including pain, an-
orexia, vaginal bleeding, cachexia, and/or psychological
problems [10], and approximately 60% of women who die
of cervical cancer have local failure as the major cause of
death [11]. Retrospective studies of radiation alone have
shown a dose–response relationship for pelvic disease
control in locally advanced cervical cancer; [12] however,
the use of higher radiation doses to improve tumor con-
trol may result in significant morbidity, particularly when
reirradiation is attempted in the salvage setting [13].
Intraoperative radiotherapy (IORT) has been used at our
institution and at others to give a focally-targeted radio-
therapy boost at the time of surgery to areas of close or
positive surgical margins to maximize radiotherapy dose
while minimizing irradiation of normal tissues [14-24].
Here we update a previous report with long-term out-
comes from the largest single-institution series of women
with locally advanced or recurrent cervical cancer treated
with a combined modality approach that includes IORT.
Methods
The Mayo Clinic Institutional Review Board (IRB) approved
this study. We queried the prospectively-maintained IORT
database for patients with cervical carcinoma treated with
IORT at Mayo Clinic, Rochester, MN from 1980 to 2010.
All patients were treated with a combined modality ap-
proach that included, at a minimum, surgery and IORT.
Patients selected for this approach had either locally ad-
vanced primary cervix cancer with pelvic wall extension
and/or extensive paraaortic (PA) lymph node (LN) involve-
ment or locally recurrent cervix cancer within the pelvis
and/or abdomen. In addition to having pathologically-
confirmed disease, patients underwent a multidisciplinary
evaluation that included a radiation oncologist and a gyne-
cologic oncologist. In cases where chemotherapy wasdeemed appropriate, a medical oncologist was also involved
in all decision making.
Details regarding the administration of IORT at Mayo
Clinic have been described previously [25] and are sum-
marized as follows. IORT is delivered in a dedicated
operating suite. All patients in this study were treated
using high-energy electrons (IOERT) from a linear accel-
erator. IOERT was delivered employing one of a series
of custom-made Lucite collimating devices of various
lengths, shapes, and diameters, selected to best encom-
pass the at-risk field. The dose was prescribed to the
90% isodose level such that ≥90% of the prescription
dose was delivered to the margin in question. Resection
margins were graded based on the both the surgeon’s
subjective assessment and the frozen pathologic assess-
ment prior to the delivery of IOERT as R0 (microscopic-
ally negative), R1 (microscopically positive), or R2 (grossly
positive). Dose was selected based on the amount of re-
sidual disease and proximity of critical structures. Routine
follow-up after IOERT consisted of pelvic examination
every three months with surveillance imaging of the abdo-
men and pelvis every six months for two years. Follow-up
thereafter consisted of physical examination with imaging
annually or as indicated by symptoms.
Clinical data including patterns of failure, survival, and
toxicity were recorded prospectively in the IORT database
through patient visits or contact with local physicians. All
endpoints were defined from the date of IOERT. Deter-
mination of disease progression was made based on radio-
graphic and/or physical exam findings. Central control
(CC) was defined as freedom from recurrence within the
IOERT field. Locoregional control (LRC) was defined free-
dom from recurrence within the IOERT field as well as
locoregional lymph nodes. Freedom from distant relapse
(FFDR) was defined as freedom from relapse in sites out-
side the pelvis and paraaortic region. Toxicity was scored
using the NCI Common Toxicity Criteria (CTCAE) v.4.
The Kaplan-Meier (KM) method was used to determine
cause specific (CSS) and overall survival (OS). The cumu-
lative incidence methodology was used to calculate rates
of central relapse (CR), locoregional relapse (LRR) and dis-
tant relapse (DR). For patients with recurrent cervical can-
cer, the Log-Rank test was used to assess an array of
variables for potential impact on clinical outcomes. These
variables included tumor grade (low vs. high), history of
previous radiotherapy (RT; yes vs. no), multiple previous
recurrences (yes vs. no), time period during which IOERT
occurred (1983–1996 vs. 1997–2010), time from initial
diagnosis to recurrence treated with IOERT (≤6 months
vs. >6 months), tumor size prior to IOERT (<3 cm vs.
≥3 cm), type of surgery performed in conjunction with
IOERT (pelvic exenteration vs. less invasive surgery), sur-
gical margin grade prior to delivery of IOERT (R0 vs. R1
vs. R2), pelvic sidewall involvement by tumor (yes vs. no),
Table 1 Patient and tumor characteristics at the time of






Locally advanced primary disease (n) 13/86 (15)
Recurrent disease (n) 73/86 (85)
First recurrence 59/73 (81)
Multiple previous recurrences 14/73 (19)
Previous EBRT +/− BT 59/73 (81)
Previous surgery 58/73 (79)
Previous systemic therapy 30/73 (41)
Interval from diagnosis to recurrence (mo)
Median 25.0
Range 3.1-379.4












Abbreviations: EBRT = external beam radiotherapy; BT = brachytherapy;
SCC = squamous cell carcinoma; AC = adenocarcinoma; ASC = adenosquamous
carcinoma; CC = clear cell carcinoma.
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apy (EBRT +/− BT; yes vs. no), and perioperative chemo-
therapy (yes vs. no). Variables associated with outcomes
by the Log-Rank test were then assessed using a multivari-
ate Cox proportional hazard model controlled for patient
age. These variables included tumor grade, time from ini-
tial diagnosis to recurrence treated with IOERT, history of
previous RT, type of surgery performed in conjunction
with IOERT, surgical margin grade, perioperative RT, and
perioperative systemic therapy. In all cases, a P value of
<0.05 was considered significant. All statistical analysis
was performed with JMP 8.0 (SAS Institute Inc., Cary,
NC, USA).
Results
Patient and treatment characteristics
Of the 86 patients who met criteria for inclusion in this
study, 73 (85%) had locally recurrent cervical cancer and
13 (15%) had locally advanced primary disease. The me-
dian age at IOERT was 48.6 years (range, 20.9-85.5 -
years). Most patients had squamous cell carcinoma
histology (n = 68, 79%), and the majority of tumors were
high-grade (n = 73, 85%). The median tumor size was
5.0 cm (range, 0.5-14.0 cm). Table 1 summarizes patient
and tumor characteristics at the time of IOERT.
In the 73 patients with recurrent disease, the median
time from initial cancer diagnosis to recurrent treated
with IOERT was 2.1 years (range, 0.3-31.6 years). Four-
teen (19%) of those patients had previously experienced
at least one previous local recurrence prior to IOERT.
Therapy at the time of initial diagnosis in patients
with recurrent disease consisted of primary surgery
+/− chemotherapy (n = 23, 31%), primary EBRT and
BT +/− chemotherapy (n = 18, 25%), or surgery and EBRT
+/− chemotherapy (n = 32, 44%). In all, 59 patients (81%)
with recurrent disease had previously received RT, 58
(79%) had previously undergone some form of surgery,
and 30 (41%) had previously received systemic therapy. In
the 13 patients with locally advanced primary disease, pri-
mary therapy consisted of surgery and EBRT in addition
to IOERT, with 10 of 13 patients (77%) receiving adjuvant
chemotherapy.
Treatment characteristics are summarized in Table 2.
The most common surgeries performed in conjunction
with IOERT included pelvic exenteration (n = 26, 30%)
and pelvic sidewall resection (n = 22, 26%), each occur-
ring with or without lymph node dissection (LND).
Other surgeries included paraaortic LND only (n = 17,
20%), exploration only (n = 12, 14%), radical hysterec-
tomy/LND (n = 7, 8%), abdominal wall resection (n = 1,
1%), and inguinal LND (n = 1, 1%). In all, 58 patients
(67%) were found to have tumor involving the pelvic
sidewall. The most common surgical margin grade after
maximal debulking was R0 (n = 35, 41%), but patientscommonly had either microscopic (R1; n = 30, 35%) or
gross (R2; n = 21, 24%) residual disease at the time of
IOERT. The median IOERT dose was 15 Gy (range, 6.25-
25 Gy), and the most commonly treated field was the
hemipelvis (n = 53, 61%). The most common electron
beam energy was 9 MeV (n = 44, 51%), and most patients
(n = 74, 86%) were treated with a single IOERT field.
In addition to surgical debulking and IOERT, 61 pa-
tients (71%) received peri-operative EBRT +/− BT, in-
cluding 35 patients with recurrent disease who had been
previously irradiated. EBRT was most commonly admin-
istered preoperatively, though some patients were
treated postoperatively or both pre- and postoperatively
depending on surgical findings. BT techniques changed
over the time interval in question from low-dose (LDR)
to high-dose rate (HDR) implants. The median dose for
all patients treated with perioperative RT was 45 Gy
(range, 19.8-83 Gy). For patients with recurrent disease
who had previously received RT, the median retreatment
Table 2 Treatment characteristics
Characteristic Value (%)
Surgery
Type of resection (n)
Exenteration 26 (30)
Pelvic sidewall resection 22 (26)
Paraaortic LND 17 (20)
Exploration 12 (14)
Radical hysterectomy/LND 7 (8)
Abdominal wall resection 1 (1)












Bilateral pelvis 6 (7)








IOERT cone size (cm)
Median 7
Range 5-15


















Abbreviations: LND = lymph node dissection; IOERT = intraoperative electron
beam radiotherapy; EBRT = external beam radiotherapy; BT = brachytherapy.
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any obviously overlapping fields were kept to a cumulative
dose of ≤80 Gy. Some patients (n = 41, 48%) received peri-
operative chemotherapy in addition to surgery and
IOERT. This was given concurrently with EBRT in 15
patients and sequentially in 26 patients. Systemic regimens
varied over the study time interval but universally
consisted of cisplatin-containing combination therapy.
Treatment outcomes
Median follow-up in living patients was 2.7 years (mean,
5.2 years; range, 0.1-25.5 years), and the median survival
was 15 months. Cumulative incidences of CR, LRR and
DR were 23, 38 and 43%, respectively, at 3 years (Figure 1-
A). Likewise, 3-year estimates of CSS and OS were 31 and
25% (Figure 1B). For patients with locally advanced pri-
mary disease, 3-year cumulative incidences of CR, LRR
and DR were 22, 30 and 27%. For patients with recurrent
cervical cancer, 3-year cumulative incidences of CR, LRR
and DR were 23, 39 and 44%.
On univariate analysis, no factor was found to be
prognostic for CR or LRR in patients with recurrent cer-
vical cancer (Table 3). Surgical margins were associated
with DR (p = 0.004), with 3-year cumulative DR rates of
33, 44 and 51% for patients who underwent R0, R1, and
R2 resections, respectively. This association was also true
for CSS (p = 0.04), where 3-year estimates of CSS for R0,
R1, and R2 resections were 45, 27, and 14%. The time
interval from initial diagnosis to recurrence treated with
IOERT was strongly associated with CSS (p = 0.001), and
no patient recurring within 6 months of initial diagnosis
survived 3 years. Risk factors for which no association
could be established by Log-Rank testing included tumor
grade, history of previous RT, history of multiple recur-
rences, time period during which IOERT occurred, size of
tumor recurrence, type of surgery, tumor location, delivery
of perioperative RT, and treatment with perioperative
chemotherapy.
Multivariate analysis revealed pelvic exenteration
(p = 0.02) and perioperative RT (p = 0.009) to be associ-
ated with improved CC (Table 4). The same was true for
LRC, where both pelvic exenteration (p = 0.02) and peri-
operative RT (p = 0.01) predicted for improved LRC. Sur-
























Figure 1 Cumulative incidence of central relapse (CR),
locoregional relapse (LRR), and distant relapse (DR; A) and
cause-specific (CSS) and overall survival (OS; B).
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proved FFDR compared to R2 resections; however, there
was no association when R0 and R1 resections were dir-
ectly compared. Factors associated with poor CSS included
high tumor grade (p = 0.04) and recurrence within 6 -
months of initial diagnosis (p = 0.002). No other factor was
statistically association with CSS, though trends for im-
proved CSS were seen in patients who had an R0 (p = 0.07)
or R1 (p = 0.08) resection compared to an R2 resection or
who received perioperative RT (p = 0.07).
Toxicity
Toxicity graded as being potentially related to delivery of
IOERT (effects that may not have occurred if IOERT had
been excluded from treatment) was reported by 30 pa-
tients (35%). The most serious was a bowel perforation
that led to a patient’s death. Other serious side effects in-
cluded one grade 4 bowel perforation as well as cases of
ureteral stenosis (n = 4), abscess formation (n = 2), fistulaformation (n = 2), peripheral neuropathy (n = 1), he-
morrhage (n = 1), and severe soft tissue fibrosis (n = 1),
each grade 3. In all, 16 patients (19%) experienced some
degree of peripheral neuropathy, and 11 of these (13%)
required some form of long-term prescription pain
medication.
Discussion
In this study, we report the outcomes of patients with
cervical carcinoma treated with IOERT. We found that
long-term survival is possible with combined modality
therapy including IOERT for advanced cervical cancer,
even in women with poor prognostic factors, such as
pelvic sidewall disease or large tumor size. While distant
relapse after salvage therapy was a common pattern in
this population, a significant number of patients still ex-
perienced local recurrence in spite of aggressive treat-
ment. This finding underscores the challenging nature of
treating advanced cervical cancer.
Treatment for recurrent cervical cancer is usually a
function of initial cancer therapy, site of recurrence, and
patient performance status and comorbidity. In patients
treated with primary RT who experience a vaginal apex
or paravaginal tissue recurrence without pelvic sidewall
involvement, salvage rates with radical hysterectomy ap-
proach 40% in appropriately-selected patients [26,27].
Patients treated with primary surgery who experience a
vaginal cuff recurrence have a similar salvage rate when
treated with concurrent RT and cisplatin-based chemo-
therapy [6,28]. Pelvic exenteration is typically reserved
for more extensive pelvic recurrences involving the blad-
der, lower vagina, and/or rectum and can result in long-
term survival in a small percentage of patients [29-32].
When tumor involves the pelvic sidewall, as is the case
in the majority of patients in this study, salvage out-
comes are universally poor, and resection of these recur-
rences is generally considered to be futile [6,7]. In the 58
patients with pelvic sidewall involvement treated with
IOERT in this study, 3-year rates of CC, LRC, and CSS
were 69, 50, and 25%, respectively, indicating that a
small but quantifiable number of patients with pelvic
sidewall involvement can be salvaged with a combined
modality approach that includes IOERT.
Previously reported factors prognostic for improved
clinical outcomes in patients with recurrent cervical can-
cer include: disease-free interval >6 months, recurrent
tumor <3 cm in size, and no pelvic sidewall fixation [10].
On univariate analysis, we found that disease-free interval
>6 months was associated with improved CSS (p = 0.001),
but neither tumor size nor pelvic sidewall involvement
were predictive of clinical outcomes. Interestingly, surgical
margin grade (R0 vs. R1 vs. R2) was prognostic for FFDR
(p = 0.004) and CSS (p = 0.04) but did not appear to influ-
ence CC or LRC. This finding was confirmed on the
Table 3 Univariate analysis of potential prognostic risk factors in patients treated with IOERT for recurrent
cervical cancer
Variable 3-year CC, % P 3-year LRC, % P 3-year FFDR, % P 3-year CSS, % P
Tumor grade 0.68 0.61 0.46 0.21
Low 92 50 71 59
High 65 47 42 25
Previous RT 0.22 0.61 0.08 0.28
Yes 71 54 50 33
No 66 46 37 26
Multiple previous recurrences 0.95 0.20 0.77 0.72
Yes 65 45 50 32
No 71 54 47 31
Time period of IOERT 0.16 0.13 0.63 0.45
1983-1996 60 40 45 27
1997-2010 81 68 50 39
Time from diagnosis to recurrence 0.76 0.47 0.13 0.001
≤6 months 80 60 25 0
>6 months 70 52 49 34
Tumor size 0.67 0.97 0.46 0.82
<3 cm 44 35 42 22
≥3 cm 74 55 48 34
Type of surgery 0.13 0.12 0.60 0.30
Exenteration 77 58 46 41
Less extensive resection 66 49 48 27
Surgical margin grade 0.17 0.13 0.004 0.04
R0 82 71 61 45
R1 55 36 45 27
R2 81 53 25 14
Pelvic sidewall involvement 0.77 0.76 0.89 0.37
Yes 69 50 46 28
No 70 55 48 39
Perioperative RT 0.13 0.11 0.34 0.29
Yes 76 60 44 36
No 52 33 60 22
Perioperative systemic therapy 0.35 0.97 0.44 0.81
Yes 74 54 53 31
No 66 51 43 32
Abbreviations: CC = central control; LRR = locoregional control; FFDR = freedom from distant recurrence; CSS = cause-specific survival; RT = radiotherapy; IOERT =
intraoperative electron beam radiotherapy.
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(p = 0.02) resections were associated with improved FFDR,
but no correlation was found between surgical margin sta-
tus and local disease control. The finding that surgical
margin status is predictive of distant rather than local pro-
gression has been previously reported by our group [15]
and could be due to a number of factors. Firstly, an R2 re-
section may be indicative of more extensive local disease
which could in turn predict for a higher likelihood of oc-
cult distant spread, and these patients may succumb to
distant metastasis before local recurrence is detected. It isalso possible that cutting through tumor during an R2
resection may result in dissemination of tumor cells
throughout the abdominal cavity, promoting distant recur-
rence. Indeed, some groups have reported a rare but quan-
tifiable incidence of cervical cancer port site recurrences
after laparoscopic surgery, implying peritoneal spread is
possible with this malignancy [33]. Finally, cervical squa-
mous cell carcinoma (SCC) may be more radiosensitive
than other pelvic malignancies [34], which could result in
patients with SCC benefitting more from IORT than those
with other tumors. Thus, the impact of surgical margin
Table 4 Multivariate analysis of potential prognostic risk factors in patients treated with IOERT for recurrent cervical
cancer
Variable CC LRC CSS
HR 95% CI P HR 95% CI P HR 95% CI P
High grade tumor 0.92 0.17-3.97 0.91 0.78 0.24-2.14 0.64 0.40 0.14-0.96 0.04
Recurrence ≤6 months after initial therapy 0.24 0.03-4.88 0.28 0.32 0.08-2.15 0.21 0.10 0.03-0.40 0.002
Previous RT 2.21 0.57-9.00 0.25 1.26 0.43-3.51 0.66 1.40 0.60-3.20 0.43
Pelvic exenteration 4.18 1.15-20.62 0.02 3.01 1.19-8.55 0.02 1.75 0.83-3.90 0.15
Surgical margin grade
R0 vs. R2 0.69 0.13-3.52 0.65 1.60 0.56-4.61 0.38 2.25 0.94-5.42 0.07
R1 vs. R2 0.54 0.12-1.90 0.35 1.20 0.47-2.89 0.69 2.02 0.92-4.34 0.08
R0 vs. R1 1.29 0.34-5.61 0.72 1.33 0.51-3.64 0.56 1.11 0.50-2.50 0.79
Perioperative RT 5.54 1.52-23.86 0.009 3.38 1.30-9.19 0.01 2.09 0.93-4.67 0.07
Perioperative systemic therapy 0.98 0.33-3.10 0.97 0.74 0.33-1.63 0.45 0.86 0.44-1.69 0.66
Barney et al. Radiation Oncology 2013, 8:80 Page 7 of 9
http://www.ro-journal.com/content/8/1/80status on disease control within the IORT field would be
minimal, but IORT would have no effect on systemic dis-
ease control. This last scenario makes the strongest argu-
ment for including IORT as a component of treatment for
locally advanced or recurrent SCC of the cervix.
Table 5 summarizes the published literature on IORT
for cervical cancer [14,16-24]. Clinical outcomes from
the current series, including crude rate of locoregional
relapse, median survival, and OS compare favorably with







Hicks et al [18]. 1993 13 Recurrent Orthovo
Konski et al [24]. 1993 8 Primary IOER
5 Recurrent IOER
Gerard et al [17]. 1994 20 Primary IOER
34 Recurrent IOER
Stelzer et al [23]. 1995 22 Recurrent IOER
Mahé et al [19]. 1996 70 Recurrent IOER
del Carmen et al
[14].
2000 5 Recurrent IOER
Gemignani et al
[16].
2001 9 Recurrent HDR-
Martinez-Monge et
al [20].
2001 31 Primary IOER
36 Recurrent IOER
Roth et al [21]. 2003 1 Recurrent HDR-
Tran et al [22]. 2007 17 Recurrent Orthovo
Current series 2012 13 Primary IOER
73 Recurrent IOER
Abbreviations: IORT = intraoperative radiotherapy; LRR = locoregional recurrence; OS
cause-specific survival; HDR-BT = high-dose rate brachytherapy.the largest of its kind, both for total number of patients
and number of patients with recurrent cervical cancer
treated with IORT. Three other large series of note in-
clude two French studies, one of which is a single-
institution experience (n = 54) [17] and the other a
multi-institutional effort (n = 70) [19], and one other
from Spain (n = 66) [20]. Outcomes in patients with re-
current disease in the single-institutional French study
and the Spanish study were similar to those in the









ltage 15 7/13 7 -
T 20 7/8 27 -
T 20 - 9 -
T - 4/20 - 75% at 18
mos
T - 6/34 - 32% at 4 yrs
T 22 10/22 26 43% at 5 yrs
(CSS)
T 19 50/67 11 8% at 3 yrs
T 15 2/5 - -
BT 14 - - 54% at 3 yrs
T 12 6/31 - 58% at 10 yrs
T 15 18/36 - 14% at 10 yrs
BT 15 0/1 20 -
ltage 11.5 - - 47% at 5 yrs
(CSS)
T 12.5 4/13 13 29% at 3 yrs
T 17.5 33/73 17 25% at 3 yrs
= overall survival; IOERT = intraoperative electron beam radiotherapy; CSS =
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Potential reasons for this may be that only 43% of pa-
tients in that study received EBRT in addition to IORT,
only 43% of patients underwent an R0/R1 resection,
and/or patients were treated at one of several institu-
tions where the IORT procedure may not have been
common practice. Aside from the current study, the
most recent series comes from Stanford University [22],
and includes 17 patients with cervical cancer among 36
total patients with recurrent gynecologic malignancies.
They report excellent outcomes in women with recur-
rent cervical cancer at 5 years, with 45% LRC and 46%
CSS. One potential reason for these seemingly superior
outcomes at 5 years is that only 32% of the patients from
the Stanford series had pelvic sidewall involvement,
compared to 67% in the current series. Additionally,
18% of the patients in the Stanford series underwent ex-
enteration, while 30% had an exenteration in our study,
implying a more advanced disease state in the patients
treated at our institution. Another interesting difference
between these studies is that the Stanford data showed
no benefit to exenteration compared to less extensive
surgery, while in our series, exenteration predicted for
improved CC and LRC. The reason for this difference is
unclear but may in part be due to sampling error, as only
7 patients underwent exenteration in the Stanford series.
Overall, the median survival after IORT in the studies
summarized in Table 5 ranged from 7–27 months, and
OS ranged from 8-54% at 3 years.
Conclusions
While the current study is retrospective in nature and
subject to the usual elements of bias and uncertainty, it
provides evidence to support the concept that a small
but significant proportion of women with locally ad-
vanced or recurrent cervical cancer may experience
long-term survival after combined modality therapy in-
cluding IOERT. Because treatment-related morbidity
with this approach can be severe, it must be balanced
against both the likelihood of cure and the risk of mor-
bidity from untreated local disease. Good candidates for
combined modality therapy with IOERT include women
with a disease-free interval >6 months who will tolerate
pelvic exenteration if necessary. If possible, perioperative
RT with concurrent chemotherapy should be strongly
considered, even in previously irradiated patients, as the
delivery of perioperative RT was associated with im-
proved LRC. Patients who do not meet these criteria
should be considered for a less aggressive approach that
may involve palliative RT and/or surgery, along with pal-
liative chemotherapy.
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